USA - Ekhbary News Agency
Science Corporation, the venture founded by former Neuralink president Max Hodak, is on the cusp of a groundbreaking advancement in neurotechnology. After two years of discussions, Dr. Murat Günel, chair of Yale Medical School’s Neurosurgery Department, has joined as a scientific advisor. His primary objective is to oversee the first U.S. human trials for the company's biohybrid brain-computer interface, culminating in the surgical placement of its initial sensor into a patient's brain.
Read Also
→ Trump Urges China to Secure Strait of Hormuz Ahead of Beijing Summit Amid Hesitation→ Al Jazeera Condemns Killing of Journalist in Gaza Strike→ Devialet Phantom Ultimate 108 dB Wireless Speaker Review: Sound Refined and RedefinedThis cutting-edge interface aims to eventually combine lab-grown neurons with electronics, offering a novel approach to treating neurological conditions and potentially enhancing human capabilities. The company, established in 2021, recently closed a $230 million Series C funding round, valuing it at $1.5 billion. Their most advanced product, PRIMA, is designed to restore vision for patients with conditions like macular degeneration. However, Hodak's overarching vision is to establish robust communication links between computers and the human brain, paving the way for disease treatment and the development of new human senses.
